Citadel Advisors’s Entrada Therapeutics TRDA Stock Holding History

Citadel Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.71M	Sell	215,018 -77,752	-27%	-$891K	﹤0.01%	5465
2025 Q4	$3.01M	Sell	292,770 -42,971	-13%	-$362K	﹤0.01%	5152
2025 Q3	$1.95M	Buy	335,741 +235,384	+235%	+$1.38M	﹤0.01%	6121
2025 Q2	$674K	Buy	100,357 +83,904	+510%	+$675K	﹤0.01%	7925
2025 Q1	$149K	Sell	16,453 -54,216	-77%	-$676K	﹤0.01%	10887
2024 Q4	$1.22M	Sell	70,669 -17,555	-20%	-$318K	﹤0.01%	6617
2024 Q3	$1.41M	Sell	88,224 -42,225	-32%	-$665K	﹤0.01%	6180
2024 Q2	$1.86M	Buy	130,449 +60,773	+87%	+$864K	﹤0.01%	5451
2024 Q1	$987K	Buy	+69,676	New	+$985K	﹤0.01%	6938
2022 Q3	–	Sell	-12,947	Closed	-$158K	–	13624
2022 Q2	$158K	Sell	12,947 -51,452	-80%	-$390K	﹤0.01%	10939
2022 Q1	$604K	Sell	64,399 -44,395	-41%	-$476K	﹤0.01%	8939
2021 Q4	$1.86M	Buy	+108,794	New	+$2.64M	﹤0.01%	6418

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's TRDA Position: Q1 2026 in Review

Citadel Advisors reduced its Entrada Therapeutics (TRDA) stake by 27% in Q1 2026, selling an estimated $891K and leaving 215,018 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #5465.

Citadel Advisors first reported a position in TRDA in Q4 2021 and has held it in 12 quarters since. The position peaked at $3.01M in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

Citadel Advisors held 215,018 shares of Entrada Therapeutics worth $2.71M as of Q1 2026.
Citadel Advisors sold 77,752 Entrada Therapeutics shares in Q1 2026, an estimated $891K.
Entrada Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5465 holding.
Citadel Advisors first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 12 quarters since.
Citadel Advisors's Entrada Therapeutics position peaked at $3.01M in Q4 2025.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.